Il Dong Pharmaceutical Co., Ltd.

Yearin Jun

Gunhee Kim

Jin Hee Lee

Kyung Mi An

Te-ik Sohn

Changmok Oh

Jung Ho Kim

Jeong-Geun Kim

Hong Chul Yoon

Jung-eun Park

Da Hae Hong

Jae Eui Shin

Changhee Hong

Woo Jin Jeon

Min Whan Chang

In-Gyu Je

Yeongran Yoo

Ji Hye Choi

A-rang Im

Eun Hye Jang

Jaeho Heo

Kyeojin Kim

Myong Jae Lee

Jin Ah Jeong

Sung Wook Kwon

Jung Woo Lee

Joontae Park

Dami Lim

Jinsun Kwon

Ilji Jeong

Kyeong-A Kim

Jungho Kim

Jaeeun Ryu

A-Rang Im

Hongchul Yoon

Jongmin Yoon

Myongjae Lee

Seolhee Lee

Jooyun Lee

Jung-Eun Park

Te-Ik Sohn

Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

GLP-1 receptor agonist and use thereof

The present disclosure provides CFTR modulator and phosphodiesterase 4 (PDE4) inhibitor compounds of the formula (Ia): and compositions including said compounds. The compounds can provide functionality for modulating CFTR, methods for treating an eye disease or disorder, and methods for treating CFTR-related indications. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE4 in a biological system or biological sample, for treating an inflammatory disease or disorder, and for treating other PDE4-related indications. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators

Growing community of inventors

Gyeonggi-do, South Korea

Yearin Jun